HPS Pharmacies wish to advise that all suppliers are experiencing a supply interruption for trimethoprim products, as follows:
|Product||ARTG||Estimated return date|
Trimethoprim 300mg tablets
|Triprim®||11009||Early March 2023|
|Trimethoprim Viatris||338350||Mid-January 2023|
Trimethoprim + sulfamethoxazole
|Resprim® tablets (80mg/400mg)||17681||Mid December 2022|
|Resprim® Forte tablets (160mg/800mg)||17682||Early February 2023|
|Septrin® Forte tablets (160mg/800mg)||10998||Late January 2023|
|DBL™ Sulfamethoxazole 400mg and Trimethoprim 80mg/5 mL ampoule||16293||Late February 2023|
Internationally registered brands of trimethoprim 300mg tablets and sulfamethoxazole and trimethoprim 400mg/80mg ampoules have been approved for supply under Section 19A of the Therapeutic Goods Act 1989.
Septrin® Suspension (trimethoprim + sulfamethoxazole) is not currently affected by this supply interruption.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates